United States Pemetrexed Market Size & Outlook, 2025-2033


United States Pemetrexed Market Insights

  • Based on Reed Intelligence findings, the United States Pemetrexed Market reached USD 633.64 Million in 2024 and is estimated to attain USD 730.37 Million by 2033.
  • From 2026 to 2033, the United States market is expected to grow at a steady CAGR of 1.66%.
  • Within the By Application category, Malignant Pleural Mesothelioma dominated in 2024 in terms of market size contribution.
  • Over the forecast period, Non-Squamous NSCLC is forecasted to deliver the fastest growth, positioning it as the most lucrative By Application segment.

Other Key Findings


  • United States contributed 27.08% to the global Pemetrexed Market size in 2024.
  • By 2033, United States is forecasted to remain the largest global market for Pemetrexed Market.
  • In North America, United States is projected to capture the leading share of market size by 2033.
  • Among North America markets, Canada is expected to post the fastest growth, reaching USD 287.86 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 633.64 Million
Market Size In 2033 USD 730.37 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.66% (2025-2033)
Segmnetation Covered
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends